HUYA Bioscience International has formed a strategic partnership with the Tianjin Institute of Pharmaceutical Research (TIPR). The collaborative agreement will promote advancement of China’s drug innovations.
HUYA and TIPR will collaborate to promote new drug development in China and worldwide. HUYA will have the first opportunity to evaluate certain R&D projects conducted at TIPR and provide support and assistance as needed. With its unique co-development model and worldwide pharmaceutical partners, HUYA will help globalize select programs from TIPR.
“The Tianjin Institute of Pharmaceutical Research is exactly the kind of top-level partner we are seeking in China,” said Clement Gingras, HUYA’s CTO and COO, China.
Dr. Lida Tang, president of TIPR, believes the strategic partnership with HUYA can help take TIPR compounds to the next level in development, testing and commercialization. “There is no doubt we have the scientific basis to come up with novel drug compounds. With HUYA we now have the international expertise to make a global impact.”